June 15, 2021
Video
Drs Richard S. Isaacson and Marc E. Agronin look to the future of treating Alzheimer disease with the emphasis on early diagnosis.
June 15, 2021
Video
The use of blood-based biomarkers for diagnosis of Alzheimer disease in the context of the comprehensive diagnosis.
June 15, 2021
Video
Impact of the approval of aducanumab on the treatment landscape and other drugs in development for the treatment of Alzheimer disease.
June 15, 2021
Video
The challenges of identifying the appropriate patient, earlier in the disease course, for treatment with aducanumab for Alzheimer disease.
June 15, 2021
Video
The importance of the ongoing EMBARK phase III clinical trial and the collection of real-world data on the use of aducanumab is discussed.
June 15, 2021
Video
Expert neurologists, Richard S. Isaacson, MD, and Marc E. Agronin, MD, describe the journey to the FDA approval of aducanumab for the treatment of Alzheimer disease and what this means for clinicians.
Serum Neurofilament Light Poses as Critical Biomarker During Ataxic, Preataxic Stages of Spinocerebellar Ataxias
Connecting ALS: How New Drug Coverage Decisions Are Made
NeuroVoices: Mark Lew, MD, on the Validation of Tears as a Biomarker for Parkinson Disease
AlzoSure Predict Test Shows Predictive Ability for Alzheimer Disease Years Prior to Diagnosis